Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

13.56
+0.69505.40%
Volume:896.53K
Turnover:12.21M
Market Cap:1.04B
PE:-9.42
High:13.95
Open:13.09
Low:12.97
Close:12.86
52wk High:13.95
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:0.72
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:8.22
PE(LYR):-18.80

Loading ...

Candel Therapeutics Files Form 3 for Chief Commercial Officer Mark E. Sims

Reuters
·
Jul 09

Candel Therapeutics Grants New CCO Mark Sims Options for 285,000 Shares at $10.03 Each

Reuters
·
Jul 09

Candel Therapeutics Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 09

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 09

Candel Therapeutics Posts Corporate Presentation on Cancer Immunotherapy Pipeline Led by Can-2409 and Can-3110 Programs

Reuters
·
Jul 08

Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Jul 07

Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Common Shares for $70,151.20

Reuters
·
Jul 02

Candel Therapeutics Grants New Hire Options for 25,000 Shares at $10.3 Each

Reuters
·
Jul 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 02

Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-cancer Drug

Dow Jones
·
Jun 30

Candel Therapeutics Launches Phase 3 Aurora Trial of Can-2409 Combo in Advanced NSCLC

Reuters
·
Jun 30

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec (can-2409) in Advanced Non-small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

THOMSON REUTERS
·
Jun 30

Candel Therapeutics Names Mark Sims Chief Commercial Officer

Reuters
·
Jun 25

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

THOMSON REUTERS
·
Jun 25

Candel Therapeutics Stockholders Approve Directors and Auditor

TIPRANKS
·
Jun 25

Candel Therapeutics Shareholders Elected Four Class II Directors at Annual Meeting

Reuters
·
Jun 25

Candel Therapeutics Updates Employment Agreement with Chief Financial Officer

TIPRANKS
·
Jun 17

Candel Therapeutics CFO Schoch employment agreement keeps base salary at $468,600, bonus target 40%

Reuters
·
Jun 17

Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target

TIPRANKS
·
Jun 03

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

TIPRANKS
·
Jun 02